Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
haloperidol + ketamine
- Development stage
- Phase 4
- Lead developer
- Johnson & Johnson
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
A combination of haloperidol, a high-potency first-generation antipsychotic, and ketamine, an NMDA receptor antagonist with dissociative anesthetic properties. This combination is used for managing acute agitation, delirium, and pain in emergency settings. Haloperidol works primarily through dopamine D2 receptor antagonism, while ketamine blocks NMDA receptors. The combination provides rapid sedation with complementary effects - haloperidol can reduce some cognitive impairments produced by ketamine while maintaining effective sedation.
02
Targets
DRD2 (Dopamine D2 Receptor)KOR (Kappa opioid receptor)MOR (Mu opioid receptor)mAChR (Muscarinic acetylcholine receptors)NMDAR (Glutamate receptor ionotropic, NMDA)
Beyond the preview
Go deeper on haloperidol + ketamine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on haloperidol + ketamine.